en.Wedoany.com Reported - Profusa, a Nasdaq-listed company headquartered in Berkeley, California, announced that it has signed a Letter of Intent to acquire the PanOmics™ multi-omics diagnostics platform from BioInsights. This move marks the commercial-stage digital health company's formal extension of its business reach from real-time biochemical monitoring into the molecular diagnostics field, aiming to build a comprehensive healthcare platform that integrates biosensing, diagnostics, and precision diagnostics.
The core of this strategic expansion lies in tackling the medical challenge of pancreatic cancer. Profusa plans to deeply integrate the newly acquired PanOmics platform with its core Lumee® real-time biochemical monitoring platform. Through its previously announced in-depth collaboration with the world-renowned medical institution Mayo Clinic, Profusa will gain critical access to clinical samples and a clear validation pathway. This collaboration aims to address the complex intraoperative and postoperative monitoring challenges in pancreatic surgery, providing patients with differentiated surgical monitoring solutions.
Dr. Ben Hwang, Chairman and CEO of Profusa, noted that this transaction not only adds $30 million in shareholder equity to the company's balance sheet but also lays the foundation for establishing a scalable business presence in the precision diagnostics field. By achieving breakthroughs in pancreatic cancer applications, the company will be positioned to support long-term growth across more indications and accelerate clinical adoption. Profusa is committed to leveraging its tissue-integrated sensor technology to provide clinicians with trustworthy, medical-grade, personalized biochemical monitoring data, driving precision diagnostic technology towards commercial success.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
